Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
September 19 2023 - 3:15PM
Business Wire
All test groups demonstrated statistically
significant benefit in broiler health under simulated commercial
conditions
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a
biotech/agtech R&D company engaged in the development of
therapeutic, medicinal and nutritional product candidates derived
from proprietary algal cultures, announces positive results from a
month-long coccidiosis trial in broiler chickens that was conducted
by an independent veterinary research provider. The study
evaluating the Company’s novel immune-modulating biologic for
treating coccidiosis in broiler chickens examined multiple product
lots as well as multiple product test concentrations and produced
statistically significant positive outcomes in the treated
groups.
Coccidiosis is a protozoal disease that causes diarrhea, weight
loss, decreased performance, and increased mortality in poultry.
This disease represents a significant economic challenge for the
global poultry industry, as indicated by a 2020 study that
estimated annual costs ranging from $10 billion to $17 billion
(Re-calculating the Cost of Coccidiosis in Chickens; Blake, D.,
Knox, J., et al.). Products for treating coccidiosis are mostly
antibiotic or ionophore-based, and no commercially significant new
technology has been introduced in the past 60 years.
The disease challenge used in this trial closely replicated
conditions often seen in commercial broiler production facilities
experiencing a coccidiosis outbreak, including commercially
relevant incidence and severity of intestinal lesions, mortality,
and other disease related measures. Birds treated with ZIVO’s
product candidate demonstrated statistically significant
improvements across all measures of broiler health examined.
Diseased chickens treated with elevated doses of ZIVO's product
candidate exhibited reductions in disease-related effects to a
level seen in healthy birds.
“These results are very encouraging as they demonstrate our
product’s potential to mitigate the effects of coccidiosis while
acting through a highly desirable non-antibiotic mechanism of
action. We now plan to launch the final phase of the product
candidate’s validation, which involves a 42-day confirmatory study
performed under broiler industry-relevant conditions such as those
used in the present study. We expect to have results from this
confirmatory study near the end of 2023,” said John Payne, CEO and
Chairman of ZIVO Bioscience.
The results of this recent study of multiple product batches,
including product used in the inconclusive study earlier this year,
align with those of over 20 prior successful trials that closely
replicated disease levels observed in commercial production
settings. Thus, validating that ZIVO’s product candidate maintains
stability over an extended period, with no decrease in its
effectiveness. As a result, ZIVO remains confident that its novel
product candidate for broiler chickens presents a disruptive
solution to coccidiosis, one of the most significant challenges
facing the global poultry industry.
"ZIVO’s biotech business is a significant driver of value
creation, and we are prioritizing our coccidiosis candidate and
working with the USDA’s Center for Veterinary Biologics on the
regulatory path toward licensure of a product for the treatment and
prevention of this disease. This strategy best optimizes value by
achieving sustainable revenue in the shortest timeframe possible.
In addition to the poultry market, our research suggests there are
numerous additional health benefits and disease treatments to be
derived from our proprietary algal culture for livestock, companion
animals, and humans. We intend to pursue those additional
opportunities, as well, should resources become available,” added
Mr. Payne.
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an
intellectual property portfolio comprised of proprietary algal and
bacterial strains, biologically active molecules and complexes,
production techniques, cultivation techniques and patented or
patent pending inventions for applications in human and animal
health. Please visit www.zivobioscience.com for more
information.
Forward Looking Statements
Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, including with respect
to the Company’s product candidate’s potential to generate revenues
and the expected time frame for results of future studies. Words
such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions or variations of such
words are intended to identify forward-looking statements. Although
ZIVO believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our strategic partnerships may not facilitate
the commercialization or market acceptance of our products; risks
that we will be unable to increase production sufficient to meet
our expected demand; risks that our products may not be ready for
commercialization in a timely manner or at all; risks that our
products will not perform as expected based on results of our
pre-clinical and clinical trials; our ability to raise additional
funds; uncertainties inherent in the development process of our
products; changes in regulatory requirements or decisions of
regulatory authorities; the size and growth potential of the
markets for our products; the results of clinical trials, our
ability to protect our intellectual property rights and other
risks, uncertainties and assumptions, including those described
under the heading “Risk Factors” in our filings with the Securities
and Exchange Commission. These forward–looking statements speak
only as of the date of this press release and ZIVO undertakes no
obligation to revise or update any forward–looking statements for
any reason, even if new information becomes available in the
future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230919835336/en/
ZIVO Bioscience Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130 kmarchiando@zivobioscience.com
LHA Investor Relations Tirth T. Patel (212) 201-6614
tpatel@lhai.com
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Apr 2024 to May 2024
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From May 2023 to May 2024